Biogen Reports observational Data for Bevacizumab in Atopic dermatitis

Biogen today announced observational results for bevacizumab in patients with atopic dermatitis. The study demonstrated that bevacizumab improves functional outcomes compared to standard of care or placebo. These results provide important insights into the treatment of atopic dermatitis and support the continued development of bevacizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.